Medicare Part D and Its Impact on the Elderly
With the implementation of Medicare Part D, seniors and those under age 65 with permanent disabilities, have experienced an increased
Read More
Part D/Prescription Drugs
Pfizer makes 2nd price hike this year for nearly 100 drugs: 4 things to know
(By Mackenzie Bean for Becker’s Hospital Review) Pfizer on June 1 increased the U.S. list prices for nearly 100 drugs
Read MoreAnticipating Drug Pricing Plans from the Trump Administration
Two of the top pharmaceutical executives’ Jose Jimenez, CEO Novartis and Brent Saunders, CEO of AllerganPlc, anticipate proposals from the
Read MoreCoaching Overdose Survivors to Avoid the Next One
(By Christine Vestal for Stateline) published June 2, 2017 NEW YORK — Five months into his job at a 24-hour
Read MoreHHS makes $70M in grants available to address opioid epidemic
(By Brian Zimmerman for Becker’s Hospital Review) HHS Secretary Tom Price, MD, on Wednesday said the agency will offer more
Read MoreKratom with a side of cheesesteak: A sub shop’s vending machine draws customers desperate to kick opioids
(By Eric Boodman for STAT) TUCSON, Ariz. — Besides the psychoactive properties of eggplant parm and mid-century nostalgia, there isn’t
Read MoreA Drug Quintupled in Price. Now, Drug Industry Players Are Feuding Over the Windfall.
(By Charles Ornstein, ProPublica, and Katie Thomas, The New York Times, May 31, 2017) A company that manages prescription drug
Read MoreOhio’s Attorney General Suing Drug Manufacturers
On Wednesday the Attorney General for the state of Ohio, Mike DeWine, filed a suit against five major drug manufacturers
Read MoreMylan may have overcharged taxpayers by $1.27 billion for EpiPens, HHS says
(By Ike Swetlitz for STAT) Mylan may have overcharged taxpayers as much as $1.27 billion over 10 years for its signature
Read MoreDrug Rebates Reward Industry Players — And Often Hurt Patients
(By Sarah Jane Tribble for Kaiser Health News) Medicare and its beneficiaries aren’t the winners in the behind-the-scenes rebate game
Read More